EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma

Respiratory Medicine

Volumn 100, Issue 7, 2006, Pages 1152-1162

  Dahl, Ronald ^a   Chuchalin, Alexander ^b   Gor, Dee ^c   Yoxall, Sally ^c   Sharma, Raj ^c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Research Institute of Pulmonology   (Russian Federation)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Adults; Exacerbations; Formoterol budesonide; Persistent asthma; Salmeterol fluticasone

Indexed keywords

ANTIBIOTIC AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID DERIVATIVE; FLUTICASONE PROPIONATE PLUS SALMETEROL; PREDNISOLONE; SALBUTAMOL;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DYSPHONIA; FEMALE; HEADACHE; HOARSENESS; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PARALLEL DESIGN; PHARYNGITIS; POPULATION RESEARCH; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; THRUSH;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33744531845     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2006.03.001     Document Type: Article

References (16)

1. Greening A.P., Ind P.W., Northfield M., and Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 344 (1994) 219-224
2. Woolcock A., Lundback B., Ringdal N., and Jacques L.A. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 153 (1996) 1481-1488
3. van Noord J.A., Schreurs A.J., Mol S.J., and Mulder P.G. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax 54 (1999) 207-212
4. Condemi J.J., Goldstein S., Kalberg C., Yancey S., Emmett A., and Rickard K. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group. Ann Allergy Asthma Immunol 82 (1999) 383-389
5. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention: NHLBI/WHO Workshop Report. National Institutes of Health, National Heart Lung and Blood Institute, 2002.
6. British Thoracic Society (BTS). Asthma guidelines. Thorax 58 Suppl 1 (2003) 1-93
7. Aubier M., Pieters W.R., Schlosser N.J.J., and Steinmetz K.-O. Salmeterol/fluticasone propionate (50/500 μg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 93 (1999) 876-884
8. Shapiro G., Lumry W., Wolfe J., et al. Combined salmeterol 50 μg and fluticasone propionate 250 μg in the Diskus device for the treatment of asthma. Am J Respir Crit Care Med 161 (2000) 527-534
9. Chapman K.R., Ringdal N., Backer V., Palmqvist M., Saarelainen S., and Briggs M. Salmeterol and fluticasone propionate (50/250 mcg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. Can Respir J 6 (1999) 45-51
10. Bateman E.D., Britton M., Carrillo J., Almeida J., and Wixon C. Salmeterol/fluticasone combination inhaler. A new, effective and well tolerated treatment for asthma. Clin Drug Invest 16 (1998) 193-201
11. Pauwels R.A., Lofdahl C.G., Postma D.S., et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol And Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 337 (1997) 1405-1411
12. Ringdal N., Chuchalin A., Chovan L., Tudoric N., Maggi E., and Whitehead P.J. Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of Seretide (50/250 μg bid Diskus) vs. formoterol (12 μg bid) and budesonide (800 μg bid) given concurrently (both via Turbuhaler) in patients with moderate-to-severe asthma. Respir Med 96 (2002) 851-861
13. Bateman E.D., Boushey H.A., Bousquet J., et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am J Respir Crit Care Med 170 (2004) 836-844
14. McFadden Jr. E.R., and Warren E.L. Observations on asthma mortality. Ann Intern Med 127 (1997) 142-147
15. Dahl R., Larsen B.B., and Venge P. Effect of long-term treatment with inhaled budesonide or theophylline on lung function, airway reactivity and asthma symptoms. Respir Med 96 (2002) 432-438
16. Pedersen B., Dahl R., Karlstrom R., Peterson C.G., and Venge P. Eosinophil and neutrophil activity in asthma in a one year trial with inhaled budesonide. The impact of smoking. Am J Respir Crit Care Med 153 (1996) 1519-1529